ViroMissile Appoints Michael G. Wood as Chief Business Officer
SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV(TM) (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Michael G. Wood as Chief Business Officer. In this role, Mr. Wood will lead ViroMissile's corporate strategy, fundraising, and partnering activities as the company advances its proprietary IDOV(TM) […]